Ascentage Pharma Group Internat (AAPG) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.44B and a free-cash-flow yield of -13.2%. Over the most recent reported fiscal year, revenue declined 41.5%. Nama's AI scorecard rates it Sell, 2.2 out of 10. On 12-month momentum it ranks in the trailing band of its market.
AI scorecard
Sell · 2.2/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Trailing · -53.8% over 12 months ex. last
Bottom 20% of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-68.2%
How far the last close sits under the highest price of the past five years.
Market cap
$1.44B
Trailing P/E
—
Price / book
70.1
Price / sales
15.0
FCF yield
-13.2%
Dividend yield
—
Gross margin
93.9%
Operating margin
-248.9%
Net margin
-228.5%
Revenue growth (YoY)
-41.5%
Revenue growth (3-yr annual)
+39.9%
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.7
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
AAPG analyst price target
Median target $45.50 from 10 analysts, ranging $33.00 – $55.00.
Nama's AI scorecard currently rates Ascentage Pharma Group Internat Sell (2.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the AAPG price target?
The median analyst price target from 10 analysts is $45.50, with a range of $33.00 – $55.00.
Is AAPG Shariah compliant?
Nama's AAOIFI-style screen reads Ascentage Pharma Group Internat as Can't Tell. A figure the screen needs is missing, so it can't tell.